PULMONARY HISTOPLASMOSIS IN A PATIENT WITH CROHN’S DISEASE ON ANTI-TNF INHIBITOR THERAPY
PULMONARY HISTOPLASMOSIS IN A PATIENT WITH CROHN’S DISEASE ON ANTI-TNF INHIBITOR THERAPY
About this item
Full title
Author / Creator
Publisher
US: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
US: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Abstract
INTRODUCTION
Infliximab, an anti-tumor necrosis factor (TNF) alpha inhibitor, is a commonly used biologic therapy for patients with inflammatory bowel disease (IBD). However, the increased risk of serious infections, including both new and re-activated infections, is a major concern while patients are on this therapy. Often the prese...
Alternative Titles
Full title
PULMONARY HISTOPLASMOSIS IN A PATIENT WITH CROHN’S DISEASE ON ANTI-TNF INHIBITOR THERAPY
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3169881795
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3169881795
Other Identifiers
ISSN
1078-0998
E-ISSN
1536-4844
DOI
10.1093/ibd/izae020.002
